SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Akanda Corp. is a cannabis cultivation, manufacturing, and distribution company, which engages in the provision of premium quality and ethically sourced medical cannabis products to patients. The company cultivates and processes natural cannabis at facilities in the Kingdom of Lesotho, Africa and intend to supply medicinal-grade cannabis biomass, cannabis flower, and cannabis concentrates to wholesalers. It also imports and sells medical cannabis-based products. The company was founded on July 16, 2021 and is headquartered in New Romney, the United Kingdom.

Akanda Corp

Akanda Corp is experiencing a massive parabolic rally driven by an extremely low float, intense short-squeeze dynamics, and significant speculation regarding its pivot from cannabis to telecommunications infrastructure in Mexico. The community is heavily focused on the high cost-to-borrow rates and the potential for a continued squeeze, leading to heated debates between bullish traders capitalizing on the momentum and skeptical observers warning of potential dilution and volatility.

Senseonics Holdings, Inc. is a medical technology company, which engages in the development and manufacture of glucose monitoring products. Its primary product is the brand Eversense CGM (continuous glucose monitoring) including sensors, smart transmitters, and mobile applications. The company was founded on June 26, 2014 and is headquartered in Germantown, MD.

Senseonics Holdings Inc

Senseonics Holdings is facing intense community backlash following the announcement of an 80 million dollar public offering of common stock and pre-funded warrants. Investors are expressing significant frustration over the resulting dilution, concerns regarding potential future reverse splits, and deep dissatisfaction with the company's capital management and leadership performance.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivian is facing heightened market scrutiny ahead of its earnings report as investors debate the impact of significant capital expenditure and dilution risks against the potential growth catalyst of the R2 platform. While some community members remain optimistic about long-term production scaling and the company's strategic partnerships, others are concerned about cash burn, share dilution, and executive compensation packages amidst a volatile electric vehicle market.

Reddit, Inc. operates an entertainment, social networking, and news website where registered community members can submit content. The firm provides online news services where users can select and rank web content. It also offers a personalized filter on the day's story, using previous votes to determine what new things the user might like to read. The company was founded by Steven Ladd Huffman and Alexis Ohanian on June 23, 2005 and is headquartered in San Francisco, CA.

Reddit Inc. - Ordinary Shares - Class A

Reddit Inc

Reddit is trending as investors monitor the company's Q1 performance, characterized by significant revenue and EPS beats alongside robust user growth. The community is actively debating the stock's future trajectory, with some optimistic about its potential for a squeeze and long-term monetization, while others remain cautious regarding potential post-earnings volatility and broader software sector pressures.

Roblox Corp. engages in the provision of online gaming services. Its platform consists of Roblox Client, Roblox Studio, and Roblox Cloud. Roblox Client is an application that allows users to explore 3D digital worlds. Roblox Studio is the toolset that allows developers and creators to build, publish, and operate 3D experiences and other content accessed with Roblox Client. Roblox Cloud includes the services and infrastructure that power the human co-experience platforms. The company was founded by Erik Cassel and David B. Baszucki in March 2004 and is headquartered in San Mateo, CA.

Roblox Corporation - Ordinary Shares - Class A

Roblox Corp.

Roblox stock is currently reeling after a sharp post-earnings selloff, driven by lowered guidance, engagement concerns, and ongoing scrutiny over platform safety and user growth deceleration. While some community members view the dip as an attractive long-term entry point given the company's strong FCF and active user base, others remain skeptical, citing persistent profitability issues and potential regulatory risks.

Dogelon Mars

Dogelon Mars continues to trend due to persistent community efforts to drive social engagement and high-frequency trading chatter despite significant historical volatility. Investors are actively discussing the potential for long-term growth driven by speculative hype, meme culture, and hopes for major exchange listings.

Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of immunotherapies to treat cancer and autoimmune diseases. Its products include CUE-400 series (autoimmune diseases), CUE-500 series (targeted cell depletion), and CUE-100 series (Oncology). The company was founded by Ronald D. Seidel III, Steven Almo, and Rodolfo Chaparro on December 31, 2014 and is headquartered in Boston, MA.

Cue Biopharma Inc

Cue Biopharma is currently experiencing extreme volatility and heavy volume as traders react to a recent preclinical milestone payment and an upcoming R&D presentation, while others express deep skepticism regarding the company's long-term performance and potential reverse split. The community is sharply divided, with bulls pointing to fundamental technology developments and Big Pharma partnerships, while bears highlight persistent dilution, management concerns, and a downward trend in share price.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA is currently experiencing significant downward volatility despite a broader market rally, as investors weigh ongoing AI demand against concerns over hyperscalers developing custom silicon alternatives. The community remains deeply divided, with many long-term holders treating the pullback as a buying opportunity while active traders and option holders express intense frustration over recent price manipulation and technical resistance levels.

NIO, Inc. operates as a holding company, which engages in the design, development, manufacture, and sale of smart electric vehicles. It offers its products under the brands NIO, ONVO, and FIREFLY. The company was founded by Bin Li and Li Hong Qin on November 28, 2014 and is headquartered in Shanghai, China.

NIO Inc - ADR

NIO Inc

NIO is trending as the community debates the impact of upcoming vehicle delivery data, ongoing battery swap expansion milestones, and the company's competitive positioning following recent model launches. Investors remain divided, with many expressing frustration over persistent price volatility and institutional participation while others emphasize the long-term potential of the firm's battery-as-a-service infrastructure.

Zeta Global Holdings Corp. operates as a marketing technology software company, which engages in the provision of enterprises with consumer intelligence and marketing automation software. It enables its customers to target, connect and engage consumers through software that delivers marketing across all addressable channels, including email, social media, web chat, connected TV and video among others. The company was founded by David A. Steinberg and John Sculley on May 9, 2012 and is headquartered in New York, NY.

Zeta Global Holdings Corp - Ordinary Shares - Class A

Zeta Global Holdings Corp

Zeta Global is attracting significant community attention as investors debate its long-term potential following a strong earnings report that featured a 50% year-over-year revenue increase. While some participants express frustration with recent price volatility and bearish sentiment, many others are focused on the company's aggressive R&D spending and the successful adoption of its AI-driven platform as key catalysts for future growth.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Erasca (NASDAQ:ERAS) Trading 8.8% Higher - What's Next?

Erasca (NASDAQ:ERAS) Trading Up 8.8% - Time to Buy...

Erasca stock sinks almost 50% after patient death in cancer drug trial

A 66-year-old man developed severe lung inflammation about a month after starting ERAS-0015 and later died after withdrawing supportive care...

Erasca (NASDAQ:ERAS) Sees Large Volume Increase on Analyst Upgrade

Erasca (NASDAQ:ERAS) Sees Strong Trading Volume After Analyst Upgrade...

Dow Gains 150 Points; Coca-Cola Posts Upbeat Earnings

US stocks mixed with Dow up 150 pts. Dow up 0.27%, NASDAQ down 1.06%, S&P 500 down 0.52%. Energy shares up 1.7%. Coca-Cola beats earnings & raises guidance. Baiya Int'l up 126%, Nexera up 63...

Why Is Cancer Drug Developer Erasca Stock Plunging On Tuesday?

Erasca reports early ERAS-0015 data showing tumor response while rejecting Revolution Medicines' patent and trade secret allegations.read more...

<ul class="summary-bullets"><li>The death followed Grade 3 pneumonitis in a 66-year-old pancreatic cancer patient receiving a 24 mg dose.</li><li>ERAS-0015 showed strong early tumor response rates, including 62% in KRAS-mutant lung cancer.</li><li>Additional data from the Auroras-1 trial are expected in 2027, while results from its other candidate, ERAS-4001, are expected later this year.</li></ul>Shares of Erasca, Inc. (ERAS) plunged nearly 40% in extended trading on Monday after investors spotted a treatment-related death buried within safety disclosures, even as the company flagged strong early tumor response rates from a Phase 1 study of its experimental cancer therapy ERAS-0015.<a href="https://stocktwits.com/symbol/ERAS">ERAS stock</a> slid nearly 11% on Monday, logging its worst session in nearly eight months.&nbsp;<h2 class="st-heading-2">Treatment-Related Death Surfaces In ERAS Phase 1 Trial</h2>According to a fresh filing, one patient experienced Grade 3 pneumonitis that progressed to a treatment-related death. The patient was a 66-year-old male with metastatic pancreatic cancer receiving a 24 mg dose of ERAS-0015 who had pulmonary metastases and prior lung procedures before entering the study.&nbsp;The patient later discontinued treatment after developing pneumonitis one month after therapy initiation and later died following withdrawal of supportive care.<h2 class="st-heading-2">ERAS Cancer Trial Shows Strong Early Cancer Responses&nbsp;</h2>Alongside the safety update, Erasca reported strong early response signals from the company’s Auroras-1 study across KRAS-mutant cancers. In previously treated non-small cell lung cancer, ERAS-0015 showed a 62% tumor response rate at eight weeks, rising to 75% among patients who had already received immunotherapy and platinum chemotherapy. In pancreatic cancer, the therapy showed a 40% response rate at fourteen weeks, with most responding patients still on treatment at the time of analysis.The company also reported that all 14 evaluable patients showed large reductions in circulating tumor DNA levels. Based on these results, Erasca selected 24 mg and 32 mg once daily as the doses to move forward into expansion studies.&nbsp;Looking ahead, the company expects additional monotherapy expansion and combination dose-escalation data from the Auroras-1 study in the first half of 2027. Preliminary Phase 1 data for ERAS-4001, its pan-KRAS inhibitor program, is expected in the second half of this year.<h2 class="st-heading-2">RevMed Patent Claims Add Pressure&nbsp;</h2>Separately, Erasca disclosed in the new filing that it received a letter from the legal counsel for Revolution Medicines alleging that ERAS-0015 may infringe compositions claimed in a U.S. patent under the doctrine of equivalents. The letter also alleged possible trade-secret misappropriation from a third-party patent relating to ERAS-0015 and challenged comparisons between ERAS-0015 and RMC-6236 made in public disclosures.RMC-6236 is a cancer drug being developed by Revolution Medicines to treat tumors driven by KRAS mutations. Unlike older targeted therapies that focus on a single mutation, it works across multiple KRAS mutation types, which are common in cancers such as lung and pancreatic cancer. It is still in early-stage clinical testing.Revolution Medicines requested that Erasca cease manufacturing, using or selling ERAS-0015 outside Hatch-Waxman safe-harbor protections and stop making “untrue comparative statements.” However, Erasca said it believes the allegations are without merit and intends to contest them vigorously.<h2 class="st-heading-2">How Do Retail Traders Feel About ERAS?</h2>On Stocktwits, retail sentiment for ERAS slipped to ‘bearish’&nbsp; from ‘neutral’ levels from a day ago amid ‘extremely high’ message volume.<figure class="image"><img src="https://news.stocktwits-cdn.com/eras_ss_png_c88c88c3a3.webp" alt="eras ss.png" width="980" height="152"><figcaption>ERAS sentiment and message volume as of April 28 | Source: Stocktwits</figcaption></figure>One user&nbsp;<a href="https://stocktwits.com/docsamiles/message/651583972">said</a>, “Long-term effert on stock price depends on Erasca's relationship with FDA and whether a clinical hold is issued. Honesty and timeliness is paramount in FDA interactions.”<stembedurl>https://stocktwits.com/docsamiles/message/651583972</stembedurl>Another user&nbsp;<a href="https://stocktwits.com/FDAvalid/message/651581652">said</a>, “The Reality Check: If a drug makes a patient "decide" to stop all care, the toxicity is the problem, not the patient. You aren't buying a dip; you're buying a bio-hazard.”<stembedurl>https://stocktwits.com/FDAvalid/message/651581652</stembedurl>ERAS stock has surged nearly 1,300% over the past year.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/lucid-stock-crash-retail-eye-saudi-pif-buyout/cZB8j0uRe5d">Lucid Stock Is Crashing Hard And Leaves Retail Wondering If Saudi PIF Buyout Is A Good Exit Strategy</a>

In this photo illustration, the Erasca logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

ERAS Stock Slumps Nearly 40% After-Hours: Fine Print In 'Positive' Cancer Trial Reveals Treatment-Related Death 

ERAS Stock - Meanwhile, Revolution Medicines has alleged potential patent infringement and trade-secret issues related to ERAS-0015.

Equity

Meanwhile, Revolution Medicines has alleged potential patent infringement and trade-secret issues related to ERAS-0015.

Erasca Shares Phase 1 ERAS-0015 Data: 62% NSCLC Response, ctDNA Clearance Signals

Erasca (NASDAQ:ERAS) presented a preliminary Phase 1 data update for ERAS-0015 (also referred to as ERAS-15), which management described as a pan-RAS molecular glue, highlighting early signals of...

Erasca (NASDAQ:ERAS) Shares Gap Down - What's Next?

Erasca (NASDAQ:ERAS) Shares Gap Down - What's Next...

Stifel Nicolaus Issues Positive Forecast for Erasca (NASDAQ:ERAS) Stock Price

Stifel Nicolaus upped their price target on shares of Erasca from $20.00 to $30.00 and gave the company a "buy" rating in a report on Monday...

Erasca (NASDAQ:ERAS) Stock Price Down 6.3%  - Time to Sell?

Erasca (NASDAQ:ERAS) Shares Down 6.3% - Time to Sell...

Erasca, Inc. is a clinical stage precision oncology company. It focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. It has assembled a wholly owned or controlled RAS/MAPK pathway focused pipeline comprising modality-agnostic programs. The company was founded by Jonathan E. Lim and Kevan Shokat on July 2, 2018 and is headquartered in San Diego, CA.

Current Price	$10.65
Prev Close	$9.11
Open	$9.14
Dividend Yield	0.00%
50-Day Moving Average	$15.73
Beta	1.36
Avg. Volume	5.63M
PE Ratio	-24.24

52-Week High	$24.28
52-Week Low	$1.06
Market Capitalization	$2.83B
EPS (Annual)	-$0.4393
Price to Book	9.31
Revenue Per Employee	$0.00

ERAS
Erasca Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ERAS News

ERASErasca Inc